ý

Kidney Health Evaluation

Percentage of patients aged 18-75 years with a diagnosis of diabetes who received a kidney health evaluation defined by an Estimated Glomerular Filtration Rate (eGFR) AND Urine Albumin-Creatinine Ratio (uACR) within the 12-month measurement period.

Date Reviewed: May 9, 2024
Do Not Support: Not Tested
    Health Plan
Support
    Group/Practice Individual Clinician

Measure Info

MIPS 488 HEDIS KED
Measure Type
Process
Measure Steward
National Kidney Foundation
Clinical Topic Area
Diabetes
Care Setting
Outpatient
Data Source
Claims
Registry

ACP supports “Kidney Health Evaluation” at the individual physician and group practice levels. The measure aims to improve the rates of accurate kidney health evaluation in diabetic patients to treat or delay the progression of chronic kidney disease. There are concerns with overuse, since Urine Albumin-Creatinine Ratio (uACR) testing should not be conducted annually in all people with diabetes. The measure developer should consider aligning the measure with the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline, which outlines a comprehensive approach to management for patients with diabetes and kidney disease. The testing sample for reliability and validity is small but sufficient to demonstrate the performance measure’s scientific acceptability. The performance measure needs exclusions for patients on ACE or ARB therapy or sodium–glucose cotransporter-2 (SGLT-2) inhibitors. There are some feasibility concerns regarding the data elements captured through free text, which can lead to issues with EHR mapping. ACP does not support this measure at the health plan level since there is no testing data.